Literature DB >> 35066761

Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy.

T S Usenko1,2, K A Senkevich3,4, A I Bezrukova3, G V Baydakova5, K S Basharova3, A S Zhuravlev3, E V Gracheva6, A V Kudrevatykh6, I V Miliukhina4,6, I V Krasakov7, L A Khublarova8, I V Fursova8, D V Zakharov8, A A Timofeeva4, Y A Irishina6, E I Palchikova8, N M Zalutskaya8, A K Emelyanov3,4, E Y Zakharova5, S N Pchelina3,4,9.   

Abstract

The synucleinopathies are a group of neurodegenerative diseases characterized by the oligomerization of alpha-synuclein protein in neurons or glial cells. Recent studies provide data that ceramide metabolism impairment may play a role in the pathogenesis of synucleinopathies due to its influence on alpha-synuclein accumulation. The aim of the current study was to assess changes in activities of enzymes involved in ceramide metabolism in patients with different synucleinopathies (Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)). The study enrolled 163 PD, 44 DLB, and 30 MSA patients as well as 159 controls. Glucocerebrosidase, alpha-galactosidase, acid sphingomyelinase enzyme activities, and concentrations of the corresponding substrates (hexosylsphingosine, globotriaosylsphingosine, lysosphingomyelin) were measured by liquid chromatography tandem-mass spectrometry in blood. Expression levels of GBA, GLA, and SMPD1 genes encoding glucoceresobridase, alpha-galactosidase, and acid sphingomyelinase enzymes, correspondently, were analyzed by real-time PCR with TaqMan assay in CD45 + blood cells. Increased hexosylsphingosine concentration was observed in DLB and MSA patients in comparison to PD and controls (p < 0.001) and it was associated with earlier age at onset (AAO) of DLB (p = 0.0008). SMPD1 expression was decreased in MSA compared to controls (p = 0.015). Acid sphingomyelinase activity was decreased in DLB, MSA patients compared to PD patients (p < 0.0001, p < 0.0001, respectively), and in MSA compared to controls (p < 0.0001). Lower acid sphingomyelinase activity was associated with earlier AAO of PD (p = 0.012). Our data support the role of lysosomal dysfunction in the pathogenesis of synucleinopathies, namely, the pronounced alterations of lysosomal activities involved in ceramide metabolism in patients with MSA and DLB.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Enzyme activity; Gene expression; Lysosomal storage disorders; Substrate concentration; Synucleinopathies

Mesh:

Substances:

Year:  2022        PMID: 35066761     DOI: 10.1007/s12035-021-02688-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  31 in total

Review 1.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

2.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 3.  Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.

Authors:  Silvia Paciotti; Leonardo Gatticchi; Tommaso Beccari; Lucilla Parnetti
Journal:  Clin Chim Acta       Date:  2019-03-25       Impact factor: 3.786

4.  Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.

Authors:  Laurie A Robak; Iris E Jansen; Jeroen van Rooij; André G Uitterlinden; Robert Kraaij; Joseph Jankovic; Peter Heutink; Joshua M Shulman
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

5.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization.

Authors:  N Tayebi; M Callahan; V Madike; B K Stubblefield; E Orvisky; D Krasnewich; J J Fillano; E Sidransky
Journal:  Mol Genet Metab       Date:  2001-08       Impact factor: 4.797

Review 6.  In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.

Authors:  Amir Tayaranian Marvian; David J Koss; Farhang Aliakbari; Dina Morshedi; Tiago Fleming Outeiro
Journal:  J Neurochem       Date:  2019-05-15       Impact factor: 5.372

7.  Mutation analysis of Parkinson's disease genes in a Russian data set.

Authors:  Anton K Emelyanov; Tatiana S Usenko; Christelle Tesson; Konstantin A Senkevich; Mikhail A Nikolaev; Irina V Miliukhina; Alena E Kopytova; Alla A Timofeeva; Andrey F Yakimovsky; Suzanne Lesage; Alexis Brice; Sofya N Pchelina
Journal:  Neurobiol Aging       Date:  2018-07-09       Impact factor: 4.673

8.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

9.  Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2.

Authors:  Friederike Zunke; Lisa Andresen; Sophia Wesseler; Johann Groth; Philipp Arnold; Michelle Rothaug; Joseph R Mazzulli; Dimitri Krainc; Judith Blanz; Paul Saftig; Michael Schwake
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-21       Impact factor: 11.205

10.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.